Iron deficiency anemia is a common type of anemia, which is a result of decreased level of haemoglobin in red blood cells (RBCs). There are several causes for iron deficiency anemia, such as inadequate iron intake, pregnancy or blood loss due to menstruation, internal bleeding, and body’s inability to absorb iron. The symptoms observed in patients with iron deficiency anemia are fatigue, weakness, pale skin, dizziness, a tingling or crawling feeling in the legs, cold hands and feet, irregular heartbeat, brittle nails, and headache. Pregnant women, people who donate blood frequently, premature infants, and vegetarians are at a higher risk of developing iron deficiency anemia. Pieris Pharmaceuticals Inc. is in the process of developing PRS-080 as an anticalin against hepcidin for the treatment of iron deficiency anemia. Some other companies involved in iron deficiency anemia pipeline are FibroGen Inc., Akebia Therapeutics Inc., and Rockwell Medical, Inc. among others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.